Group 1 - The article highlights the increasing importance of women in the business sector, as evidenced by the Third Asian Women Entrepreneurs Conference, which gathered nearly 400 outstanding female representatives from various industries to discuss and reshape the essence of business leadership [1] - The concept of leadership is evolving, with a shift towards valuing resonance, collaboration, flexibility, and inclusivity over traditional notions of control and dominance, particularly in the context of female leaders [2] - Female leaders are increasingly focusing on health management as a strategic asset, utilizing personalized and comprehensive approaches such as traditional Chinese dietary therapy to maintain overall balance and long-term resilience [2][4] Group 2 - The article discusses the significance of kidney essence in determining anti-aging potential, noting that aging in women often begins with kidney essence deficiency, leading to various health issues [4] - Research indicates that the detection rate of breast nodules among female entrepreneurs is projected to exceed 65% by 2028, and the osteoporosis detection rate among women over 60 is approximately double that of their male counterparts [4] - The Ba Zi Bu Shen capsule, a product that integrates traditional wisdom with modern research, has gained attention for its effectiveness in addressing anti-aging concerns among professional women [5][8] Group 3 - The Ba Zi Bu Shen capsule has successfully entered markets in eight countries, including Canada and Singapore, and has seen over 226 million capsules consumed domestically, primarily by women aged 35 and above [8] - The article emphasizes the need for women leaders to continuously accumulate and maintain their physical and mental health energy in the context of a rapidly changing global business landscape [9] - The focus on systemic nourishment and functional enhancement reflects a broader trend among elite women, moving beyond superficial changes to deeper health management strategies [9][10]

Core Viewpoint - Guangyuyuan's subsidiary, Shanxi Guangyuyuan, has received a registration certificate for the non-prescription traditional Chinese medicine, An Gong Niu Huang Wan, from the Macao SAR government's drug regulatory authority, which will aid in expanding its overseas market presence [1] Group 1 - The registration application for An Gong Niu Huang Wan was submitted on May 7, 2025 [1] - The medicine is indicated for clearing heat and detoxifying, and its traditional production technique has been recognized as a national intangible cultural heritage [1] - The projected sales revenue for this product in the relevant market for 2024 is approximately 498.242 million yuan [1] Group 2 - The approval of An Gong Niu Huang Wan is expected to assist the company in expanding its international market reach [1] - The impact of this approval on the company's current performance is not expected to be significant [1]

Core Viewpoint - Guangyuyuan (600771.SH) has received a Traditional Chinese Medicine registration certificate for its product "An Gong Niu Huang Wan" from the Macao SAR government, marking a significant step in expanding its market presence in Macao [1] Group 1: Company Developments - Guangyuyuan's subsidiary, Shanxi Guangyuyuan National Medicine Co., Ltd., submitted the registration application for "An Gong Niu Huang Wan" on May 7, 2025 [1] - The product is recognized as a classic formula in traditional Chinese medicine, with historical roots tracing back to the Qing Dynasty [1] Group 2: Product Information - "An Gong Niu Huang Wan" is indicated for treating heat diseases, including high fever, convulsions, and various neurological conditions [1] - The traditional production technique of "An Gong Niu Huang Wan" has been included in the national intangible cultural heritage list, highlighting its cultural significance [1]

证券代码：600085 证券简称：同仁堂 公告编号：2025-042 北京同仁堂股份有限公司 第十届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、会议召开情况 北京同仁堂股份有限公司（以下简称公司或本公司）第十届董事会第十八次会议于2025年12月30日在公 司会议室以现场结合通讯会议方式召开。本次会议通知已提前送达全体董事，与会各位董事均已知悉与 本次会议所议事项的相关必要信息。本次董事会会议应出席董事11人，实际出席11人。公司部分高级管 理人员列席了本次会议。会议由董事长张朝华女士主持，会议的召开和表决程序符合《中华人民共和国 公司法》及《北京同仁堂股份有限公司章程》（以下简称《公司章程》）的有关规定。 二、会议审议情况 (一) 审议通过了《关于与关联方签订采购框架性协议及预计年发生额度的预案》 公司拟与控股股东中国北京同仁堂（集团）有限责任公司（以下简称同仁堂集团）签订《采购框架性协 议》，协议期限三年，公司及下属子公司向同仁堂集团（含其附属公司，不含本公司）采购原材料、药 品、保健食 ...

Core Insights - The article highlights the surge in demand for traditional Chinese medicine, particularly in the context of the ongoing H3N2 influenza outbreak in China, with a positive detection rate exceeding 30% and H3N2 subtype accounting for over 95% of cases [1][2] Industry Overview - The flu season has officially begun in China, with activity levels expected to peak between mid-December and early January [1] - The demand for flu medications has skyrocketed, with JD Health reporting a more than 13-fold year-on-year increase in sales of flu-related drugs since November [1] Company Performance - Kangyuan Pharmaceutical (600557.SH) is responding to the increased market demand by ramping up production of its products, including Jin Zhen Oral Liquid, which is expected to see a market demand rebound in Q4 [1][3] - The company has established a comprehensive product portfolio covering prevention, treatment, and rehabilitation, with key products like Heat Toxicity Ning Injection and Jin Zhen Oral Liquid effectively addressing core flu symptoms [2][3] - Oral liquid products have become the company's largest revenue source, generating 1.359 billion yuan in revenue in the first three quarters of 2025, accounting for 58% of total revenue, a significant increase from 20% in 2024 [2] Market Dynamics - The sales of traditional Chinese medicines such as Ganmao Ling Granules and Xiao Chai Hu Granules have seen over 100% month-on-month growth, indicating strong consumer preference [2] - The company is well-positioned to capitalize on the current market environment, which is seen as a critical opportunity for performance recovery, particularly with the ongoing flu season [3]

Group 1 - Beijing Tongrentang Group has taken over the management of Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd. and has dismissed the general manager Li Shengyi due to the "Antarctic Krill Oil" incident [1] - The group confirmed that the authorization for the "Tongrentang" brand and trademark for Sichuan Health expired on March 21, 2021, and has not been renewed [1] - The group is cooperating with a joint investigation by government regulatory bodies and has submitted evidence related to the infringement by Sichuan Health [1] Group 2 - The group has initiated a special action for strict brand management, conducting thorough checks on brand usage across its subsidiaries, with over 520 inspections completed by December 24 [1] - Nearly 600 complaints have been filed against infringing products on major e-commerce platforms, targeting over 120 unauthorized stores using the "Tongrentang" name [1] - A product verification system was launched on the official website, providing information on over 1,000 products, including traditional Chinese medicine and health foods, to guide consumers [2]

Core Viewpoint - Tongrentang Group is taking significant measures to address issues related to brand management and consumer protection following a scandal involving a product mislabeling incident, particularly concerning Antarctic krill oil products [1][3][8]. Group 1: Accountability and Investigation - The company has initiated a comprehensive investigation into the responsibilities of involved parties, confirming that the trademark authorization for "Tongrentang" to Sichuan Health expired on March 21, 2021, and was not renewed [1][6]. - A task force led by senior management has been established to take over the operations of Sichuan Health, resulting in the dismissal of its general manager and the suspension of other relevant personnel [1][6]. - The company is cooperating with regulatory authorities and has submitted evidence related to the infringement by Sichuan Health, while actively recalling and removing the implicated products from circulation [1][6]. Group 2: Brand Protection Measures - Tongrentang has launched a product information query system to help consumers identify genuine products marked with the "Double Dragon" logo, with over 1,000 items available for verification [2][7]. - A brand management initiative has been implemented, resulting in over 520 inspections of affiliated units and stores, and nearly 600 complaints filed against infringing products on major e-commerce platforms [2][7]. - The company is taking legal action against entities misusing the "Tongrentang" name and is committed to enforcing strict brand management practices [3][9]. Group 3: Consumer Rights and Product Safety - In response to consumer concerns regarding the Antarctic krill oil product, the company has expressed deep regret and is taking immediate actions to ensure compliance and consumer compensation [3][8]. - The company is conducting thorough checks for any illegal or irregular brand usage across its enterprises to enhance consumer protection [9].

Group 1 - The core message of the news is that Tongrentang Group is taking significant actions to address the issues related to the unauthorized use of its brand and products, particularly in response to the controversy surrounding a product claiming to contain Antarctic krill oil [1][7][9] Group 2 - Tongrentang Group has initiated a comprehensive investigation and accountability measures, including the dismissal of the general manager of Sichuan Health Company and the suspension of other responsible personnel [1] - The company is actively cooperating with regulatory authorities in a joint investigation and has taken steps to recall the problematic products while monitoring their distribution channels [2] - A product information query system has been launched to help consumers identify genuine Tongrentang products, emphasizing the importance of the "Double Dragon Mark" for authenticity [3] - A special action for strict brand management has been initiated, resulting in the inspection of over 520 units and the filing of nearly 600 complaints against infringing products and stores [4] Group 3 - The Shanghai Consumer Protection Committee has identified serious discrepancies in the marketing of a product claiming to contain 43% phospholipids, which was found to contain none, leading to a formal investigation [7][8] - The company has acknowledged unauthorized use of its brand by Sichuan Health Company and has initiated legal proceedings against the involved parties [8] - Regulatory bodies are planning to implement stricter oversight on commissioned production practices to ensure product quality and consumer protection [9]

针对消费者反映的产品辨伪问题，集团提示：正规"同仁堂"品牌产品清晰印制"双龙标"，商标也作为官 方授权店铺的统一标识；12月23日，同仁堂集团产品查询系统已在官网上线，开放1000余条涵盖中成 药、保健食品等品类产品的信息查询服务，提供权威购买指引。 本文转自【新华社微信公众号】； 记者：张骁 事件发生后，北京同仁堂集团已启动品牌严管专项行动，对各级企业品牌使用情况开展拉网式核查，截 至12月24日，累计排查所属单位/店铺520余次；对重点电商平台上侵权产品和店铺链接进行排查，累计 完成侵权产品投诉近600项；对"同仁堂正品直售""北京同仁堂滋补佳品"等120余个冒用"同仁堂"名义的 违规店铺发起投诉，坚决打击"擦边"使用"同仁堂"字号、商标使用不规范等行为。 北京同仁堂集团25日就"南极磷虾油"事件发布声明称，集团工作组已全面接管北京同仁堂（四川）健康 药业有限公司经营管理工作，责令李声义辞去四川健康总经理职务，并对其他相关管理人员全部予以停 职。后续将根据政府监管部门及内部调查结论，对相关失职失责人员严肃处理。 北京同仁堂集团表示，经查，集团对四川健康"同仁堂"字号及商标授权已于2021年3月21日到期， ...

Group 1 - The core product launched by China Resources Jiangzhong is a new formulation of the classic "Liuwei Dihuang Wan," transitioning from pill to paste form, designed for modern fast-paced lifestyles [1] - The traditional Chinese medicine market for kidney tonics is projected to reach 48.73 billion yuan in 2024, with a year-on-year growth of 9.2%, indicating a significant consumer trend towards health products that are efficient and convenient [1] - The new product features a portable design with independent packaging, enhancing convenience for users while also focusing on taste by incorporating honey for a sweet and slightly sour flavor [1] Group 2 - A representative from China Resources Jiangzhong emphasized that this innovation reflects the company's commitment to providing convenient health solutions and its role as a leader in the inheritance and innovation of traditional Chinese medicine [2] - Alibaba Health stated its role as a launch platform for new specialty drugs, aiming to provide consumers with easy access to health products, with many regions offering same-day or next-day delivery for the new product [2]